Targeting CD30 in anaplastic large cell lymphoma

Current Hematologic Malignancy Reports

Volumn 7, Issue 4, 2012, Pages 285-291

  Vadakara, Joseph ^a   Pro, Barbara ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; Brentuximab; CD30; MMAE; SGN 35; T cell lymphoma; Vedotin

Indexed keywords

ADCETRIX; AFM 13; ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IRATUMUMAB; MDX 1401; MOMORDIN; MONOCLONAL ANTIBODY 2513; PRALATREXATE; PREDNISONE; ROMIDEPSIN; SGN 30; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FAILURE FREE SURVIVAL; FATIGUE; HODGKIN DISEASE; HUMAN; IN VIVO STUDY; LARGE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RADIOIMMUNOASSAY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84872199040     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0137-y     Document Type: Article

References (59)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
2. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK-Anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111 (12):5496-504. doi:10.1182/blood-2008-01-134270.
3. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol. 1996;14 (3):955-62.
4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-6. doi:10.1056/NEJM199304083281404. (Pubitemid 23095683)
5. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159-66.
6. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14 suppl 1:i5-10. doi:10.1093/annonc/mdg702.
7. Velasquez W, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117-22.
8. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP -An effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12(6):1169-76.
9. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-9. doi:10.1200/jco.2010.29.9024.
10. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827-34. doi:10.1182/blood-2010-10-312603.
11. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase ii study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631-6. doi:10.1200/jco.2011.37.4223.
12. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68(3):421-7. doi:10.1016/0092-8674(92)90180-k.
13. Stein H, Mason D, Gerdes J, O'Connor N,Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-58.
14. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1-14.
15. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457-70. doi:10.1006/smim.1998.0156.
16. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133(3):446-50.
17. Gruss H, Boiani N, Williams D, Armitage R, Smith C, Goodwin R. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83(8):2045-56.
18. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, et al. Tumor necrosis factor receptor-Associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFκB activation. J Biol Chem. 1997;272(4):2042-5. doi:10.1074/jbc.272.4.2042. (Pubitemid 27058475)
19. Mir SS, Richter BWM, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13):4307-12.
20. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R, et al. Phase I/II Study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764-9. doi:10.1200/jco.2006.07.8972. (Pubitemid 47123185)
21. Bartlett NL, Younes A, Carabasi MH, Forero A, Rosenblatt JD, Leonard JP, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848-54. doi:10.1182/blood-2007-07-099317.
22. Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-9. doi: 10.1111/j.1365-2141.2009.07740.x.
23. Hammond PW, Vafa O, Jacinto J, Vielmetter J, Karki S, Yoder S, et al. A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annual Meeting Abstracts). 2005;106: Abstract 1470.
24. Blum K, Smith M, Fung H, Zalevsky J, Combs D, Ramies D, et al. (editors) Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol. 2009;27(15s). Abstract 8531.
25. Cardarelli PM, Moldovan-Loomis M-C, Preston B, Black A, Passmore D, Chen T-H, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res. 2009;15(10):3376-83. doi:10.1158/1078-0432. ccr-08-3222.
26. Thertulien R, Frankel A, Evens A, Kaufman J, Horwitz S, Assad A, et al. A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkins lymphoma. Proceedings of the Annual Meeting of the American Association for Cancer Research; Apr 2009; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract 30.
27. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 2005;23(21):4669-78. doi:10.1200/jco.2005.09.098.
28. ZhangM, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci USA. 2007;104(20):8444-8. doi:10.1073/pnas.0702496104. (Pubitemid 47175507)
29. Pasqualucci L, Wasik M, Teicher B, Flenghi L, Bolognesi A, Stirpe F, et al. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic largecell lymphoma. Blood. 1995;85(8):2139-46.
30. Falini B, Flenghi L, Aversa F, Barbabietola G, Martelli M, Comeli P, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339(8803):1195-6.
31. Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, et al. Anti-CD30 (BER0H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Br J Haematol. 1996;92(4):872-9.
32. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Int J Cancer. 1996;68(3):349-55.
33. Schneix R, Linnartz C, Katouzi AA, Schon G, Bohlen H, Horn-Lohrens O, et al. Development of new ricin A-chain immunotoxins with potent anti-Tumor effects against human hodgkin cells in vitro and disseminated Hodgkin tumors in scid mice using high-Affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer. 1995;63(2):238-44. doi:10.1002/ijc.2910630216.
34. Bolognesi A, Tazzari PL, Legname G, Olivieri F, Modena D, Conte R, et al. Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunol Immunother. 1995;40 (2):109-14. doi:10.1007/bf01520292.
35. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinköthe T, et al. Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood. 2000;95(12):3909-14.
36. Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 2002;8(6):1779-86.
37. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-65. doi:10.1182/blood- 2003-01-0039.
38. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-84.
39. Sanderson RJ, Hering MA, James SF, Sun MMC, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2):843-52.
40. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16 (3):888-97. doi:10.1158/1078-0432.ccr-09- 2069. This article describes the mechanism of action of brentuximab vedotin.
41. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5(5):543-9. doi:10.1016/j.coph.2005.04.017. (Pubitemid 41258574)
42. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21. doi:10.1056/NEJMoa1002965. First-in-human study of brentuximab vedotin.
43. Fanale M, Bartlett NL, Forero-Torres A, Rosenblatt J, Horning SJ, Franklin AR, et al. The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. Blood (Ash Annual Meeting Abstracts). 2009;114, abstract 2731. Safety and activity of brentuximab vedotin given in a weekly regimen.
44. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-6. doi:10.1200/jco.2011.38.0402. Pivotal phase II trial of brentuximab vedotin in relapsed refractory sALCL.
45. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, et al. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer. 1993;55(5):830-6. (Pubitemid 23354902)
46. Wu Y. Session 11: Therapeutic antibodies. Hum Antibodies. 2011;20(3-4):61-3.
47. Knackmuss S, Reusch U, Burkhardt C, Fucek I, Le Gall F, Pauels H-G, et al. Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma. ASCO Meeting Abstracts. 2012;30(15 suppl). e18532.
48. Rothe A, Younes A, Reiners KS, Dietlein M, Eichenauer DA, Kessler J, et al. A phase I study with the bispecific anti-CD30 x anti-CD16A antibody construct AFM13 in patients with relapsed or refractory hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 3709.
49. Shapiro R, Riordan JF, Vallee BL. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry. 1986;25(12):3527-32. doi:10.1021/ bi00360a008.
50. Barth S, Matthey B, Huhn M, Diehl V, Engert A. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma. Cytokines Cell Mol Ther. 1999;5(2):69-78.
51. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. 2001;61(24):8737-42.
52. Roskrow MA, Suzuki N, Gan Y-J, Sixbey JW, Ng CYC, Kimbrough S, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91(8):2925-34.
53. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200(12):1623-33. doi:10.1084/jem.20040890.
54. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720-4. (Pubitemid 23028937)
55. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, et al. An Anti-CD30 chimeric receptor that mediates CD3-zetaindependent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 1998;58 (6):1116-9. (Pubitemid 28183194)
56. ClinicalTrials.gov. Administration of T lymphocytes for Hodgkin's lymphoma and non-Hodgkin's lymphoma (CART CD30). http://clinicaltrials. gov/ct2/show/NCT01316146. Accessed 10 Sept 2012.
57. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181(5):1653-9. doi:10.1084/jem.181.5.1653.
58. Brocker T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000;96(5):1999-2001.
59. ClinicalTrials.gov. EBV CTLs expressing CD30 chimeric receptors for CD 30+ lymphoma (CARCD30). http://clinicaltrials.gov/ct2/show/NCT01192464. Accessed 10 Sept 2012.